Immunome Inc
Immunome Inc (IMNM) is a clinical‑stage biotechnology company focused on discovering and developing antibody-based therapies, primarily for oncology and immune-mediated diseases. The company leverages proprietary discovery platforms to identify novel antibody targets and candidates, advancing programmes into clinical trials and partnering where it can accelerate development. With a market capitalisation of about $1.46 billion, Immunome is still in the development phase and typically has limited or no product revenue; value is therefore driven by trial results, regulatory milestones and potential collaborations. Investing in Immunome means backing early-stage science with potentially high upside but notable risk: clinical outcomes are binary, timelines can be long, and spending on R&D may dilute shareholders. Investors might pay attention to clinical readouts, cash runway, partner deals and platform validation. This summary is educational only and not personal investment advice — values can rise or fall and past performance is not a guide to the future.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immunome's stock, with a target price suggesting significant growth potential.
Financial Health
Immunome Inc generates moderate revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMNM
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the stock; outcomes are binary so returns are uncertain and timelines may be long.
Science-Driven Approach
Immunome’s proprietary antibody discovery platforms could unlock differentiated candidates, though experimental science brings technical and execution risk.
Commercial Pathway
Partnerships or licensing deals could de‑risk development and fund growth, but successful commercialisation typically requires multiple positive steps.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
